ARMATA PHARMACEUTICALS ARMP 深 沪
已收盘 10-24 16:00:00 美东时间
6.06
-1.040
-14.65%
华盛通- 最 高6.69
- 今 开6.52
- 成交量 23.43万股
- 最 低 5.85
- 昨 收 7.10
- 总市值 2.20亿
- 52周最高 16.34
- 市盈率 静 --
- 换手率 0.65%
- 52周最低 0.8981
- 委 比 -33.33%
- 总股本 3622.98万
- 历史最高 16.34
- 量 比 0.08
- 振 幅 11.83%
- 历史最低 0.8311
- 每 手 1
- 风险率 0.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | ARMP大涨超103%！抗血感染药物在中期试验中显示出积极结果；直觉外科公司涨近14%
ARMP大涨超103%！抗血感染药物在中期试验中显示出积极结果；直觉外科公司涨近14%，Q3业绩表现优异，远超市场预期>>
10-23 14:51
Here’s Why Armata Pharmaceuticals Stock (ARMP) Exploded 300% Today
Armata Pharmaceuticals ($ARMP) stock exploded nearly 300% on Wednesday after th...
10-23 03:53
Armata Pharma Reports Results From Its Recently Completed Phase 2a diSArm Study Of AP-SA02 As A Potential Treatment For Complicated Staphylococcus Aureus Bacteremia In A Late-Breaking Oral Presentation At IDWeek 2025
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of
10-22 23:12
Armata Pharmaceuticals Advances Cystic Fibrosis Infection Treatment With Phage Research
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of
09-08 19:11
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
Describes the structure of phage Pa223, which is included in Armata's multi-phage anti-Pseudomonas clinical candidate, AP-PA02 LOS ANGELES, Sept. 8, 2025 /PRNewswire/ -- Armata Pharmaceutica...
09-08 19:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 21.6% to $0.52 during Wedne...
09-04 05:06
Armata Pharmaceuticals Files For Mixed Shelf Of Up To $100M
https://www.sec.gov/Archives/edgar/data/921114/000110465925077648/tm2523066d1_s3.htm
08-14 05:20
Armata Pharmaceuticals Q2 EPS $(0.45) Misses $(0.39) Estimate, Sales $2.169M Beat $1.380M Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.39) by 15.38 percent. This is a 80 percent decrease over losses of $(0.25) per share
08-13 04:32
美股机会日报丨大摩喊话超配美股！中概股业绩“大丰收”，百度、文远知行盘前齐涨
中概股业绩“大丰收”！百度、文远知行、爱奇艺盘前齐涨；大摩喊话超配美股：标普500指数将升至6500点；“木头姐”连续两日加仓台积电>>
05-21 20:14
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
